Daval International has reported positive results from a Phase II study, evaluating the safety and tolerability of Aimspro as a monotherapy to treat patients with late-stage established diffuse cutaneous systemic sclerosis.

Twenty paitents were enrolled in the double-blind, randomised and placebo-controlled study. They were given either Aimspro or placebo, 4.5mg/ml subcutaneously, twice weekly for 26 weeks.

The primary endpoint was to assess the safety and tolerability of the drug through the 26-week period.

The secondary measures included investigating the efficacy of Aimspro as a therapeutic agent for scleroderma using inter alia the Scleroderma Health Assessment Questionnaire, the Modified Rodnan Skin Score, the Scleroderma UK Functional Score, the Patient and Physician Global Assessment, the SF-36 and the MRC Sum Score.

At the end of the study, Aimspro was found to be a safe and well-tolerated medication when administered to systemic sclerosis patients at a late-stage of the disease.

Aimspro treatment combines the benefits of polyclonal antibody technology with polypeptide components.

GlobalData Strategic Intelligence

US Tariffs are shifting - will you react or anticipate?

Don’t let policy changes catch you off guard. Stay proactive with real-time data and expert analysis.

By GlobalData

Pharmaceutical Technology Excellence Awards - Have you nominated?

Nominations are now open for the prestigious Pharmaceutical Technology Excellence Awards - one of the industry's most recognised programmes celebrating innovation, leadership, and impact. This is your chance to showcase your achievements, highlight industry advancements, and gain global recognition. Don't miss the opportunity to be honoured among the best - submit your nomination today!

Nominate Now